The Beneficial Effect of Suramin on Monocrotaline-Induced Pulmonary Hypertension in Rats

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Izikki, Mohamed ^a   Mercier, Olaf ^b   Lecerf, Florence ^a,b   Lubert Guin, Lauriane ^a   Hoang, Eric ^a   Dorfmüller, Peter ^a,b   Perros, Frédéric ^a   Humbert, Marc ^a   Simonneau, Gerald ^a   Dartevelle, Philippe ^b   Fadel, Elie ^a,b   Eddahibi, Saadia ^a,b  

^a Universite Paris Sud   (France)

^b CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCROTALINE; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE; SURAMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG ARTERY PRESSURE; MALE; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; ENZYME ACTIVATION; HUMANS; HYPERTENSION, PULMONARY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MONOCROTALINE; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; PULMONARY ARTERY; RATS; RECEPTOR PROTEIN-TYROSINE KINASES; SURAMIN;

EID: 84885442413     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0077073     Document Type: Article

References (29)

1. Rabinovitch M, Gamble W, Nadas AS, Miettinen OS, Reid L, (1979) Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features. Am J Physiol 236: H818-H827. PubMed: 443445.
2. Merklinger SL, Jones PL, Martinez EC, Rabinovitch M, (2005) Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 112: 423-431. doi:10.1161/CIRCULATIONAHA.105.540542. PubMed: 16027270.
3. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, et al. (2005) Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 115: 2811-2821. doi:10.1172/JCI24838. PubMed: 16200212.
4. Izikki M, Guignabert C, Fadel E, Humbert M, Tu L, et al. (2009) Endothelial-derived FGF2 contributes to the progression of pulmonary hypertension in humans and rodents. J Clin Invest 119: 512-523. doi:10.1172/JCI35070. PubMed: 19197140.
5. Souza R, Sitbon O, Parent F, Simonneau G, Humbert M, (Aug(2006) Long term imatinib treatment in pulmonary arterial hypertension. Thorax Aug;61(8):: 736. doi:10.1136/thx.2006.064097. PubMed: 16877696.
6. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, et al. (2010) Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 1;182(9):: 1171-1177. PubMed: 20581169.
7. Hawking F, (1978) Suramin: with special reference to onchocerciasis. Adv Pharmacol Chemother 15: 289-322. doi:10.1016/S1054-3589(08)60486-X. PubMed: 358805.
8. Motzer RJ, Nanus DM, O'Moore P, Scher HI, Bajorin DF, et al. (1992) Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression. Cancer Res 52: 5775-5779. PubMed: 1394202.
9. Myers C, Cooper M, Stein C, LaRocca R, Walther MM, et al. (1992) Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 10: 881-889. PubMed: 1375283.
10. Chan YS, Li Y, Foster W, Horaguchi T, Somogyi G, et al. (2003) Antifibrotic effects of suramin in injured skeletal muscle after laceration. J Appl Physiol 95: 771-780. PubMed: 12730151.
11. Li C, Jiang X, Yang L, Liu X, Yue S, et al. (2009) Involvement of sphingosine 1-phosphate (SIP)/S1P3 signaling in cholestasis-induced liver fibrosis. Am J Pathol 175: 1464-1472. doi:10.2353/ajpath.2009.090037. PubMed: 19729475.
12. Liu N, Tolbert E, Pang M, Ponnusamy M, Yan H, et al. (2011) Suramin inhibits renal fibrosis in chronic kidney disease. J Am Soc Nephrol 22(6):: 1064-1075. doi:10.1681/ASN.2010090956. PubMed: 21617121.
13. De souza OF, Sakamoto T, Kimura H, Koda RP, Gabrielian k al (1995) Inhibition of experimental proliferative vitreoretinopathy in rabbits by suramin. Ophtalmologica. Vol. 209, no4, pp. 212-216.
14. Eddahibi S, Humbert M, Fadel E, Raffestin B, Darmon M, et al. (2001) Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest 108(8):: 1141-1150. doi:10.1172/JCI200112805. PubMed: 11602621.
15. Shi W, Eidelman DH, Michel RP, (1997) Differential relaxant responses of pulmonary arteries and veins in lung explants of guinea pigs. J Appl Physiol 83(5):: 1476-1481. PubMed: 9375308.
16. Cowan KN, Jones PL, Rabinovitch M, (1999) Regression of hypertrophied rat pulmonary arteries in organ culture is associated with suppression of proteolytic activity, inhibition of tenascin-C, and smooth muscle cell apoptosis. Circ Res 28;84(10):: 1223-1233.
17. Mekontso-Dessap A, Kirsch M, Guignambert C, Zadigue P, Adnot S, et al. (2006) Vascular-wall remodeling of 3 human bypass vessels: organ culture and smooth muscle cell properties. J Thorac Cardiovasc Surg;131(3):: 651-658. doi:10.1016/j.jtcvs.2005.08.048. PubMed: 16515919.
18. Song S, Wientjes MG, Walsh C, Au JL, (2001) Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Res 15;61Volumes 16: 6145-6150 PubMed: 11507065.
19. Zhang Y, Song S, Yang F, Au JL, Wientjes MG, (2001) Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther 299(2):: 426-433. PubMed: 11602651.
20. Leschey KH, Hines J, Singer JH, Hackett SF, Campochiaro PA, (1991) Inhibition of Growth Factor Effects in Retinal Pigment Epithelial Cells. Invest Ophthalmol Vis Sci 32(6):: 1770-1778. PubMed: 2032799.
21. Walther MM, Trahan EE, Cooper M, Venzon D, Linehan WM, (1994) Suramin inhibits proliferation and DNA synthesis in transitional carcinoma cell lines. J Urol 152(5 Pt 1):: 1599-1602. PubMed: 7933214.
22. Karam GA, Rasaee MJ, Mahmoodi M, Khaksari M, (2005) Inhibition of proteinase 3 (PR3) by suramin and fetal calf serum (FCS): effect of PR3 and suramin on Chinese hamster ovary cells (CHO-cells). Pak J Pharm Sci 18(3):: 46-48. PubMed: 16380344.
23. Takano S, Gately S, Neville ME, Herblin WF, Gross JL, et al. (1994) Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res54(10):: 2654-2660. PubMed: 7513254.
24. Zanghi JA, Renner WA, Bailey JE, Fussenegger M, (2000) The growth factor inhibitor suramin reduces apoptosis and cell aggregation in protein-free CHO cell batch cultures. Biotechnol Prog 16: 319-325. doi:10.1021/bp0000353. PubMed: 10835230.
25. Raj PA, Marcus E, Rein R, (1998) Conformational requirements of suramin to target angiogenic growth factors. Angiogenesis. 2(2):: 183-199. doi:10.1023/A:1009244623717. PubMed: 14517473.
26. Gomez-Arroyo JG, Farkas L, Alhussaini AA, Farkas D, Kraskauskas D, et al. (2012) The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol 302(4):: L363-L369. doi:10.1152/ajplung.00212.2011. PubMed: 21964406.
27. Hosang M, (1985) Suramin binds to platelet-derived growth factor and inhibits its biological activity. J Cell Biochem 29(3):: 265-273. doi:10.1002/jcb.240290310. PubMed: 4077932.
28. Williams LT, Tremble PM, Lavin MF, Sunday ME, (1984) Platelet-derived growth factor receptors form a high affinity state in membrane preparations. Kinetics and affinity cross-linking studies. J Biol Chem 259(8):: 5287-5294. PubMed: 6325430.
29. Sjölund M, Thyberg J, (1989) Suramin inhibits binding and degradation of platelet-derived growth factor in arterial smooth muscle cells but does not interfere with autocrine stimulation of DNA synthesis. Cell Tissue Res 256(1):: 35-43. PubMed: 2713895.